PT-141 (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously (abdomen or thigh). The subcutaneous route provides approximately 100% bioavailability and is better tolerated than intranasal delivery. The FDA-approved on-demand regimen uses 1.75 mg SC before intercourse (max 8 doses/month); daily protocols at 2.5 mg have been studied in obese women for appetite and weight reduction, suggesting daily use can be tolerated. This schedule uses a conservative titration starting below the FDA on-demand dose.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 3.33 mg/mL, 1 unit = 0.01 mL » 33.3 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C; use within approximately 30 days; avoid freeze-thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (PT-141, 10 mg each):

• 8 weeks: ~3 vials. 12 weeks: ~6 vials. 16 weeks: ~10 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (3 vials): 1 bottle. 12 weeks (6 vials): 2 bottles. 16 weeks (10 vials): 3 bottles.

Alcohol Swabs:

• Per week: 14 swabs.
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes (27 to 30G, 5/8 inch needle) for each injection; dispose in a sharps

container.

• Rotate injection sites (abdomen, thighs) on different days to avoid lipodystrophy or irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Nausea is the most common side effect and tends to be transient; flushing and headache may also

occur.

• Document daily dose and site rotation to maintain consistency.

How This Works

Bremelanotide is a synthetic analog of a-melanocyte-stimulating hormone that acts as a non-selective melanocortin receptor agonist, predominantly targeting MC3R and MC4R. In the central nervous system, MC4R activation enhances dopamine release in key brain reward and arousal regions including the nucleus accumbens and medial preoptic area, which increases sexual motivation and desire. Unlike PDE5 inhibitors, bremelanotide does not directly affect the nitric oxide pathway; in men, its erectogenic effect is secondary to this central mechanism stimulating nitric oxide production in penile tissue. Peripheral MC1R agonism accounts for side effects such as transient blood pressure elevation and skin hyperpigmentation (tanning).

Benefits & Side Effects

Observations from clinical trials and peer-reviewed literature.

• Clinical trials in premenopausal women with HSDD demonstrated significant improvements in sexual

desire scores (FSFI-Desire) and reduced distress (FSDS-DAO) versus placebo.

• Early studies also suggest potential benefit in men, with intranasal PT-141 improving erectile responses

and increasing arousal measures in women.

• Adverse effects: usually mild and transient: most commonly nausea (~40%), flushing, headache, and

injection-site reactions.

• Transient blood pressure increases: have been reported; not recommended for individuals with

uncontrolled hypertension or cardiovascular disease.

• Skin darkening (hyperpigmentation): may occur with repeated use due to peripheral MC1R activation

and is generally reversible.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a balanced diet and regular exercise routine to support overall hormonal health.
• Prioritize sleep quality, as poor sleep can negatively affect libido and hormonal balance.
• Manage stress through mindfulness, therapy, or relaxation techniques.
• Limit alcohol consumption, which may dampen the effects of melanocortin receptor activation.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Vyleesi (bremelanotide) prescribing information; approved 2019 for HSDD (FDA).
2. Bremelanotide for treatment of female hypoactive sexual desire: mechanism, trials, and safety review (PMC, 2022).
3. Bremelanotide (subcutaneous route): side effects, dosage, and precautions (Mayo Clinic).
4. Kingsberg SA et al. Bremelanotide for HSDD: two randomized phase 3 trials (RECONNECT, Obstet Gynecol, 2019).